{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T21:06:59Z","timestamp":1766869619255,"version":"3.37.3"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T00:00:00Z","timestamp":1496966400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005969","name":"Universit\u00e0 di Bologna","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005969","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s40264-017-0551-0","type":"journal-article","created":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T03:47:14Z","timestamp":1496980034000},"page":"823-834","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping"],"prefix":"10.1007","volume":"40","author":[{"given":"Ippazio Cosimo","family":"Antonazzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuel","family":"Raschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Vignatelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Baldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trond","family":"Riise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"D\u2019Alessandro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"De Ponti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7209-0426","authenticated-orcid":false,"given":"Elisabetta","family":"Poluzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,9]]},"reference":[{"issue":"5","key":"551_CR1","doi-asserted-by":"publisher","first-page":"A387","DOI":"10.1016\/j.autrev.2009.11.010","volume":"9","author":"R Milo","year":"2010","unstructured":"Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev. 2010;9(5):A387\u201394. doi:\n                        10.1016\/j.autrev.2009.11.010\n                        \n                    .","journal-title":"Autoimmun Rev"},{"issue":"1","key":"551_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.neurol.2015.10.006","volume":"172","author":"E Leray","year":"2016","unstructured":"Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Rev Neurol (Paris). 2016;172(1):3\u201313. doi:\n                        10.1016\/j.neurol.2015.10.006\n                        \n                    .","journal-title":"Rev Neurol (Paris)."},{"issue":"3","key":"551_CR3","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1001\/jamaneurol.2013.5993","volume":"71","author":"A Ascherio","year":"2014","unstructured":"Ascherio A, Munger KL, White R, Kochert K, Simon KC, Polman CH, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol. 2014;71(3):306\u201314. doi:\n                        10.1001\/jamaneurol.2013.5993\n                        \n                    .","journal-title":"JAMA Neurol."},{"key":"551_CR4","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516671028","author":"K Bjornevik","year":"2016","unstructured":"Bjornevik K, Riise T, Bostrom I, Casetta I, Cortese M, Granieri E, et al. Negative interaction between smoking and EBV in the risk of multiple sclerosis: The EnvIMS study. Mult Scler. 2016. doi:\n                        10.1177\/1352458516671028\n                        \n                    .","journal-title":"Mult Scler."},{"issue":"10","key":"551_CR5","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1001\/jamaneurol.2015.1788","volume":"72","author":"R Ramanujam","year":"2015","unstructured":"Ramanujam R, Hedstrom AK, Manouchehrinia A, Alfredsson L, Olsson T, Bottai M, et al. Effect of smoking cessation on multiple sclerosis prognosis. JAMA Neurol. 2015;72(10):1117\u201323. doi:\n                        10.1001\/jamaneurol.2015.1788\n                        \n                    .","journal-title":"JAMA Neurol."},{"key":"551_CR6","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jneuroim.2015.06.012","volume":"285","author":"C Pfuhl","year":"2015","unstructured":"Pfuhl C, Oechtering J, Rasche L, Giess RM, Behrens JR, Wakonig K, et al. Association of serum Epstein-Barr nuclear antigen-1 antibodies and intrathecal immunoglobulin synthesis in early multiple sclerosis. J Neuroimmunol. 2015;285:156\u201360. doi:\n                        10.1016\/j.jneuroim.2015.06.012\n                        \n                    .","journal-title":"J Neuroimmunol"},{"issue":"1","key":"551_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.msard.2014.11.008","volume":"4","author":"L Amezcua","year":"2015","unstructured":"Amezcua L, Conti DV, Liu L, Ledezma K, Langer-Goulda AM. Place of birth, age of immigration, and disability in Hispanics with multiple sclerosis. Mult Scler Relat Disord. 2015;4(1):25\u201330. doi:\n                        10.1016\/j.msard.2014.11.008\n                        \n                    .","journal-title":"Mult Scler Relat Disord."},{"key":"551_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jneuroim.2015.11.019","volume":"290","author":"N Mohammadi","year":"2016","unstructured":"Mohammadi N, Adib M, Alsahebfosoul F, Kazemi M, Etemadifar M. An investigation into the association between HLA-G 14 bp insertion\/deletion polymorphism and multiple sclerosis susceptibility. J Neuroimmunol. 2016;290:115\u20138. doi:\n                        10.1016\/j.jneuroim.2015.11.019\n                        \n                    .","journal-title":"J Neuroimmunol"},{"key":"551_CR9","unstructured":"ATLAS of MS - Mapping Multiple Sclerosis around the World. London: Multiple sclerosis International Federation; \u00a02013. Available at: \n                        https:\/\/www.msif.org\/resources\/\n                        \n                    . Accessed 1 Nov 2016."},{"issue":"4","key":"551_CR10","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/apt.12385","volume":"38","author":"P Deepak","year":"2013","unstructured":"Deepak P, Stobaugh DJ, Sherid M, Sifuentes H, Ehrenpreis ED. Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System. Aliment Pharmacol Ther. 2013;38(4):388\u201396. doi:\n                        10.1111\/apt.12385\n                        \n                    .","journal-title":"Aliment Pharmacol Ther"},{"key":"551_CR11","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1471-2288-11-92","volume":"11","author":"P Bragge","year":"2011","unstructured":"Bragge P, Clavisi O, Turner T, Tavender E, Collie A, Gruen RL. The Global Evidence Mapping Initiative: scoping research in broad topic areas. BMC Med Res Methodol. 2011;11:92. doi:\n                        10.1186\/1471-2288-11-92\n                        \n                    .","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"551_CR12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345.","journal-title":"Clin Pharmacol Ther"},{"key":"551_CR13","unstructured":"Wells GA SB, O\u2019Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2014. \n                        http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp\n                        \n                    . Accessed 05 04 2017."},{"issue":"5","key":"551_CR14","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00002018-200730050-00001","volume":"30","author":"WN Kelly","year":"2007","unstructured":"Kelly WN, Arellano FM, Barnes J, Bergman U, Edwards RI, Fernandez AM, et al. Guidelines for submitting adverse event reports for publication. Drug Saf. 2007;30(5):367\u201373.","journal-title":"Drug Saf"},{"issue":"12","key":"551_CR15","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1177\/1352458511412996","volume":"17","author":"AJ Solomon","year":"2011","unstructured":"Solomon AJ, Spain RI, Kruer MC, Bourdette D. Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors. Mult Scler J. 2011;17(12):1472\u201387. doi:\n                        10.1177\/1352458511412996\n                        \n                    .","journal-title":"Mult Scler J"},{"issue":"1","key":"551_CR16","first-page":"239","volume":"34","author":"L Bensouda-Grimaldi","year":"2007","unstructured":"Bensouda-Grimaldi L, Mulleman D, Valat JP, Leca EA. Adalimumab-associated multiple sclerosis. J Rheumatol. 2007;34(1):239\u201340.","journal-title":"J Rheumatol"},{"issue":"1","key":"551_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00296-012-2625-8","volume":"34","author":"U Uygunoglu","year":"2014","unstructured":"Uygunoglu U, Uluduz D, Tascilar K, Saip S. Multiple sclerosis during adalimumab treatment in a case with ankylosing spondylitis. Rheumatol Int. 2014;34(1):141\u20133. doi:\n                        10.1007\/s00296-012-2625-8\n                        \n                    .","journal-title":"Rheumatol Int"},{"issue":"2","key":"551_CR18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10067-012-2113-2","volume":"32","author":"T Matsumoto","year":"2013","unstructured":"Matsumoto T, Nakamura I, Miura A, Momoyama G, Ito K. New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review. Clin Rheumatol. 2013;32(2):271\u20135. doi:\n                        10.1007\/s10067-012-2113-2\n                        \n                    .","journal-title":"Clin Rheumatol"},{"issue":"1","key":"551_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/qjmed\/hcr237","volume":"107","author":"NC Hare","year":"2014","unstructured":"Hare NC, Hunt DPJ, Venugopal K, Ho GT, Beez T, Lees CW, et al. Multiple sclerosis in the context of TNF blockade and inflammatory bowel disease. Qjm. 2014;107(1):51\u20135. doi:\n                        10.1093\/qjmed\/hcr237\n                        \n                    .","journal-title":"Qjm"},{"issue":"6","key":"551_CR20","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3109\/09273948.2010.495814","volume":"18","author":"SY Li","year":"2010","unstructured":"Li SY, Birnbaum AD, Goldstein DA. Optic neuritis associated with adalimumab in the treatment of uveitis. Ocul Immunol Inflamm. 2010;18(6):475\u201381. doi:\n                        10.3109\/09273948.2010.495814\n                        \n                    .","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"551_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3109\/09546634.2012.660520","volume":"24","author":"SK Mahil","year":"2013","unstructured":"Mahil SK, Andrews TC, Brierley C, Barker JN, Smith CH. Demyelination during tumour necrosis factor antagonist therapy for psoriasis: a case report and review of the literature. J Dermatol Treat. 2013;24(1):38\u201349. doi:\n                        10.3109\/09546634.2012.660520\n                        \n                    .","journal-title":"J Dermatol Treat."},{"issue":"2","key":"551_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.cyto.2008.11.002","volume":"45","author":"A Fromont","year":"2009","unstructured":"Fromont A, De Seze J, Fleury MC, Maillefert JF, Moreau T. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine. 2009;45(2):55\u20137. doi:\n                        10.1016\/j.cyto.2008.11.002\n                        \n                    .","journal-title":"Cytokine"},{"issue":"1\u20132","key":"551_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000109576","volume":"59","author":"M Gomez-Gallego","year":"2008","unstructured":"Gomez-Gallego M, Meca-Lallana J, Fernandez-Barreiro A. Multiple sclerosis onset during etanercept treatment. Eur Neurol. 2008;59(1\u20132):91\u20133. doi:\n                        10.1159\/000109576\n                        \n                    .","journal-title":"Eur Neurol"},{"issue":"1","key":"551_CR24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jaad.2005.05.039","volume":"54","author":"SA Sukal","year":"2006","unstructured":"Sukal SA, Nadiminti L, Granstein RD. Etanercept and demyelinating disease in a patient with psoriasis. J Am Acad Dermatol. 2006;54(1):160\u20134. doi:\n                        10.1016\/j.jaad.2005.05.039\n                        \n                    .","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"551_CR25","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1212\/WNL.57.10.1885","volume":"57","author":"NL Sicotte","year":"2001","unstructured":"Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology. 2001;57(10):1885\u20138.","journal-title":"Neurology."},{"issue":"6","key":"551_CR26","first-page":"1548","volume":"26","author":"DS Titelbaum","year":"2005","unstructured":"Titelbaum DS, Degenhardt A, Kinkel RP. Anti-tumor necrosis factor alpha-associated multiple sclerosis. Am J Neuroradiol. 2005;26(6):1548\u201350.","journal-title":"Am J Neuroradiol."},{"issue":"6","key":"551_CR27","first-page":"1202","volume":"33","author":"N Al Saieg","year":"2006","unstructured":"Al Saieg N, Luzar MJ. Etanercept induced multiple sclerosis and transverse myelitis. J Rheumatol. 2006;33(6):1202\u20134.","journal-title":"J Rheumatol"},{"issue":"7","key":"551_CR28","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.clineuro.2012.09.012","volume":"115","author":"R Scheid","year":"2013","unstructured":"Scheid R. Better look (and think) twice-TNF-alpha-inhibition and multiple sclerosis. Clin Neurol Neurosurg. 2013;115(7):1195\u20136. doi:\n                        10.1016\/j.clineuro.2012.09.012\n                        \n                    .","journal-title":"Clin Neurol Neurosurg"},{"issue":"5","key":"551_CR29","doi-asserted-by":"publisher","first-page":"397-U3","DOI":"10.1080\/03009740802136164","volume":"37","author":"CF Pfueller","year":"2008","unstructured":"Pfueller CF, Seipelt E, Zipp F, Paul F. Multiple sclerosis following etanercept treatment for ankylosing spondylitis. Scand J Rheumatol. 2008;37(5):397-U3. doi:\n                        10.1080\/03009740802136164\n                        \n                    .","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"551_CR30","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/01.mcg.0000155126.82171.32","volume":"39","author":"PJ Enayati","year":"2005","unstructured":"Enayati PJ, Papadakis KA. Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis. J Clin Gastroenterol. 2005;39(4):303\u20136. doi:\n                        10.1097\/01.mcg.0000155126.82171.32\n                        \n                    .","journal-title":"J Clin Gastroenterol"},{"issue":"7","key":"551_CR31","first-page":"1457","volume":"33","author":"T Ruiz-Jimeno","year":"2006","unstructured":"Ruiz-Jimeno T, Carvajal A, Mata C, Aurrecoechea E. Demyelinating disease in a patient with psoriatic arthritis and family history of multiple sclerosis treated with infliximab. J Rheumatol. 2006;33(7):1457\u20138.","journal-title":"J Rheumatol"},{"issue":"5","key":"551_CR32","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/00042737-200605000-00021","volume":"18","author":"E Dubcenco","year":"2006","unstructured":"Dubcenco E, Ottaway CA, Chen DL, Baker JP. Neurological symptoms suggestive of demyelination in Crohn\u2019s disease after infliximab therapy. Eur J Gastroenterol Hepatol. 2006;18(5):565\u20136. doi:\n                        10.1097\/00042737-200605000-00021\n                        \n                    .","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"551_CR33","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archopht.122.5.793","volume":"122","author":"JL Mejico","year":"2004","unstructured":"Mejico JL. Infliximab-associated retrobulbar optic neuritis. Arch Ophthalmol. 2004;122(5):793\u20134.","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"551_CR34","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s00296-011-2316-x","volume":"33","author":"C Faillace","year":"2013","unstructured":"Faillace C, de Almeida JRM, de Carvalho JF. Optic neuritis after infliximab therapy. Rheumatol Int. 2013;33(4):1101\u20133. doi:\n                        10.1007\/s00296-011-2316-x\n                        \n                    .","journal-title":"Rheumatol Int"},{"issue":"4","key":"551_CR35","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1076\/ocii.10.4.299.15588","volume":"10","author":"T Matsuo","year":"2002","unstructured":"Matsuo T, Takabatake R. Multiple sclerosis-like disease secondary to alpha interferon. Ocul Immunol Inflamm. 2002;10(4):299\u2013304. doi:\n                        10.1076\/ocii.10.4.299.15588\n                        \n                    .","journal-title":"Ocul Immunol Inflamm."},{"issue":"2","key":"551_CR36","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/ajh.10090","volume":"70","author":"I Kataoka","year":"2002","unstructured":"Kataoka I, Shinagawa K, Shiro Y, Okamoto S, Watanabe R, Mori T, et al. Multiple sclerosis associated with interferon-alpha therapy for chronic myelogenous leukemia. Am J Hematol. 2002;70(2):149\u201353. doi:\n                        10.1002\/ajh.10090\n                        \n                    .","journal-title":"Am J Hematol"},{"issue":"4","key":"551_CR37","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.semarthrit.2010.06.004","volume":"40","author":"MC Fernandez-Espartero","year":"2011","unstructured":"Fernandez-Espartero MC, Perez-Zafrilla B, Naranjo A, Esteban C, Ortiz AM, Gomez-Reino JJ, et al. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. Semin Arthritis Rheum. 2011;40(4):330\u20137. doi:\n                        10.1016\/j.semarthrit.2010.06.004\n                        \n                    .","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"551_CR38","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/ard.2009.111500","volume":"69","author":"S Bernatsky","year":"2010","unstructured":"Bernatsky S, Renoux C, Suissa S. Demyelinating events in rheumatoid arthritis after drug exposures. Ann Rheum Dis. 2010;69(9):1691\u20133. doi:\n                        10.1136\/ard.2009.111500\n                        \n                    .","journal-title":"Ann Rheum Dis"},{"issue":"8538","key":"551_CR39","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0140-6736(87)92863-7","volume":"1","author":"HS Panitch","year":"1987","unstructured":"Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet. 1987;1(8538):893\u20135.","journal-title":"Lancet"},{"issue":"1\u20132","key":"551_CR40","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jns.2015.02.019","volume":"351","author":"RC Sergott","year":"2015","unstructured":"Sergott RC, Bennett JL, Rieckmann P, Montalban X, Mikol D, Freudensprung U, et al. ATON: results from a phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis. J Neurol Sci. 2015;351(1\u20132):174\u20138. doi:\n                        10.1016\/j.jns.2015.02.019\n                        \n                    .","journal-title":"J Neurol Sci"},{"key":"551_CR41","doi-asserted-by":"crossref","unstructured":"vanOosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, vonBlomberg BME, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 1996;47(6):1531\u20134.","DOI":"10.1212\/WNL.47.6.1531"},{"issue":"3","key":"551_CR42","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","volume":"53","author":"BGW Arnason","year":"1999","unstructured":"Arnason BGW, Jacobs G, Hanlon M, Clay BH, Noronha ABC, Auty A, et al. TNF neutralization in MS\u2014results of a randomized, placebo-controlled multicenter study. Neurology. 1999;53(3):457\u201365.","journal-title":"Neurology."},{"issue":"22","key":"551_CR43","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1212\/WNL.0b013e31825830a9","volume":"78","author":"D Kotzamani","year":"2012","unstructured":"Kotzamani D, Panou T, Mastorodemos V, Tzagournissakis M, Nikolakaki H, Spanaki C, et al. Rising incidence of multiple sclerosis in females associated with urbanization. Neurology. 2012;78(22):1728\u201335. doi:\n                        10.1212\/WNL.0b013e31825830a9\n                        \n                    .","journal-title":"Neurology."},{"issue":"1","key":"551_CR44","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.fertnstert.2014.03.054","volume":"102","author":"G Gava","year":"2014","unstructured":"Gava G, Bartolomei I, Costantino A, Berra M, Venturoli S, Salvi F, et al. Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis. Fertil Steril. 2014;102(1):116\u201322. doi:\n                        10.1016\/j.fertnstert.2014.03.054\n                        \n                    .","journal-title":"Fertil Steril"},{"issue":"1\u20132","key":"551_CR45","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jns.2012.02.033","volume":"317","author":"A Sena","year":"2012","unstructured":"Sena A, Couderc R, Vasconcelos JC, Ferret-Sena V, Pedrosa R. Oral contraceptive use and clinical outcomes in patients with multiple sclerosis. J Neurol Sci. 2012;317(1\u20132):47\u201351. doi:\n                        10.1016\/j.jns.2012.02.033\n                        \n                    .","journal-title":"J Neurol Sci"},{"issue":"7","key":"551_CR46","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1016\/j.fertnstert.2010.06.045","volume":"94","author":"P Holmqvist","year":"2010","unstructured":"Holmqvist P, Hammar M, Landtblom AM, Brynhildsen J. Age at onset of multiple sclerosis is correlated to use of combined oral contraceptives and childbirth before diagnosis. Fertil Steril. 2010;94(7):2835\u20137. doi:\n                        10.1016\/j.fertnstert.2010.06.045\n                        \n                    .","journal-title":"Fertil Steril"},{"issue":"9","key":"551_CR47","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1001\/archneur.62.9.1362","volume":"62","author":"A Alonso","year":"2005","unstructured":"Alonso A, Jick SS, Olek MJ, Ascherio A, Jick H, Hernan MA. Recent use of oral contraceptives and the risk of multiple sclerosis. Arch Neurol. 2005;62(9):1362\u20135. doi:\n                        10.1001\/archneur.62.9.1362\n                        \n                    .","journal-title":"Arch Neurol"},{"issue":"6","key":"551_CR48","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1212\/WNL.55.6.848","volume":"55","author":"MA Hernan","year":"2000","unstructured":"Hernan MA, Hohol MJ, Olek MJ, Spiegelman D, Ascherio A. Oral contraceptives and the incidence of multiple sclerosis. Neurology. 2000;55(6):848\u201353.","journal-title":"Neurology."},{"issue":"12","key":"551_CR49","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1111\/j.1471-0528.1998.tb10008.x","volume":"105","author":"M Thorogood","year":"1998","unstructured":"Thorogood M, Hannaford PC. The influence of oral contraceptives on the risk of multiple sclerosis. Br J Obstet Gynaecol. 1998;105(12):1296\u20139. doi:\n                        10.1111\/j.1471-0528.1998.tb10008.x\n                        \n                    .","journal-title":"Br J Obstet Gynaecol"},{"issue":"2","key":"551_CR50","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0010-7824(93)90088-O","volume":"47","author":"L Villardmackintosh","year":"1993","unstructured":"Villardmackintosh L, Vessey MP. Oral-contraceptives and reproductive factors in multiple-sclerosis incidence. Contraception. 1993;47(2):161\u20138. doi:\n                        10.1016\/0010-7824(93)90088-O\n                        \n                    .","journal-title":"Contraception."},{"issue":"5","key":"551_CR51","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1002\/ana.23745","volume":"72","author":"J Correale","year":"2012","unstructured":"Correale J, Farez MF, Ysrraelit MC. Increase in multiple sclerosis activity after assisted reproduction technology. Ann Neurol. 2012;72(5):682\u201394. doi:\n                        10.1002\/ana.23745\n                        \n                    .","journal-title":"Ann Neurol"},{"issue":"2","key":"551_CR52","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000177937","volume":"61","author":"K Hellwig","year":"2009","unstructured":"Hellwig K, Schimrigk S, Beste C, Muller T, Gold R. Increase in relapse rate during assisted reproduction technique in patients with multiple sclerosis. Eur Neurol. 2009;61(2):65\u20138. doi:\n                        10.1159\/000177937\n                        \n                    .","journal-title":"Eur Neurol"},{"issue":"4","key":"551_CR53","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s00415-008-0607-2","volume":"255","author":"K Hellwig","year":"2008","unstructured":"Hellwig K, Beste C, Brune N, Haghikia A, Muller T, Schimrigk S, et al. Increased MS relapse rate during assisted reproduction technique. J Neurol. 2008;255(4):592\u20133. doi:\n                        10.1007\/s00415-008-0607-2\n                        \n                    .","journal-title":"J Neurol"},{"issue":"6","key":"551_CR54","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1136\/oem.2005.024604","volume":"63","author":"AM Landtblom","year":"2006","unstructured":"Landtblom AM, Tondel M, Hjalmarsson P, Flodin U, Axelson O. The risk for multiple sclerosis in female nurse anaesthetists: a register based study. Occup Environ Med. 2006;63(6):387\u20139. doi:\n                        10.1136\/oem.2005.024604\n                        \n                    .","journal-title":"Occup Environ Med"},{"issue":"1","key":"551_CR55","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1136\/oem.60.1.66","volume":"60","author":"U Flodin","year":"2003","unstructured":"Flodin U, Landtblom AM, Axelson O. Multiple sclerosis in nurse anaesthetists. Occup Environ Med. 2003;60(1):66\u20138. doi:\n                        10.1136\/oem.60.1.66\n                        \n                    .","journal-title":"Occup Environ Med"},{"issue":"5","key":"551_CR56","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/ene.12098","volume":"20","author":"AK Hedstrom","year":"2013","unstructured":"Hedstrom AK, Hillert J, Olsson T, Alfredsson L. Exposure to anaesthetic agents does not affect multiple sclerosis risk. Eur J Neurol. 2013;20(5):735\u20139. doi:\n                        10.1111\/ene.12098\n                        \n                    .","journal-title":"Eur J Neurol"},{"issue":"5","key":"551_CR57","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1056\/Nejm199807303390501","volume":"339","author":"C Confavreux","year":"1998","unstructured":"Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T, Grp PMS. Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med. 1998;339(5):285\u201391. doi:\n                        10.1056\/Nejm199807303390501\n                        \n                    .","journal-title":"N Engl J Med"},{"key":"551_CR58","doi-asserted-by":"crossref","unstructured":"Browning WN. Exacerbation of symptoms of multiple-sclerosis in a patient taking fluoxetine. Am J Psychiatry. 1990;147(8):1089.","DOI":"10.1176\/ajp.147.8.1089a"},{"key":"551_CR59","doi-asserted-by":"publisher","unstructured":"Ramsaransing G, Zwanikken C, De Keyser J. Drug points\u2014worsening of symptoms of multiple sclerosis associated with carbamazepine. Br Med J. 2000;320(7242):1113. doi:\n                        10.1136\/bmj.320.7242.1113\n                        \n                    .","DOI":"10.1136\/bmj.320.7242.1113"},{"issue":"3","key":"551_CR60","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/pds.3692","volume":"24","author":"NM Nielsen","year":"2015","unstructured":"Nielsen NM, Svanstrom H, Stenager E, Magyari M, Koch-Henriksen N, Pasternak B, et al. The use of valproic acid and multiple sclerosis. Pharmacoepidemiol Drug Saf. 2015;24(3):262\u20138. doi:\n                        10.1002\/pds.3692\n                        \n                    .","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"551_CR61","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/aje\/kwj123","volume":"163","author":"A Alonso","year":"2006","unstructured":"Alonso A, Jick SS, Jick H, Hernan MA. Antibiotic use and risk of multiple sclerosis. Am J Epidemiol. 2006;163(11):997\u20131002. doi:\n                        10.1093\/aje\/kwj123\n                        \n                    .","journal-title":"Am J Epidemiol"},{"issue":"8","key":"551_CR62","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/aje\/kwr201","volume":"174","author":"M Norgaard","year":"2011","unstructured":"Norgaard M, Nielsen RB, Jacobsen JB, Gradus JL, Stenager E, Koch-Henriksen N, et al. Use of penicillin and other antibiotics and risk of multiple sclerosis: a population-based case-control study. Am J Epidemiol. 2011;174(8):945\u20138. doi:\n                        10.1093\/aje\/kwr201\n                        \n                    .","journal-title":"Am J Epidemiol"},{"issue":"6","key":"551_CR63","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.mehy.2010.08.001","volume":"75","author":"SF Kazim","year":"2010","unstructured":"Kazim SF, Shafqat S. Ethambutol-induced optic neuritis and multiple sclerosis: Is there an association? Med Hypotheses. 2010;75(6):679\u201380. doi:\n                        10.1016\/j.mehy.2010.08.001\n                        \n                    .","journal-title":"Med Hypotheses"},{"issue":"1","key":"551_CR64","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/jnnp-2014-307932","volume":"86","author":"J Gold","year":"2015","unstructured":"Gold J, Goldacre R, Maruszak H, Giovannoni G, Yeates D, Goldacre M. HIV and lower risk of multiple sclerosis: beginning to unravel a mystery using a record-linked database study. J Neurol Neurosurg Psychiatry. 2015;86(1):9\u201312. doi:\n                        10.1136\/jnnp-2014-307932\n                        \n                    .","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8686","key":"551_CR65","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/0140-6736(90)90239-2","volume":"335","author":"R Gold","year":"1990","unstructured":"Gold R, Kappos L, Becker T. Development of multiple-sclerosis in patient on long-term sulfasalazine. Lancet. 1990;335(8686):409\u201310. doi:\n                        10.1016\/0140-6736(90)90239-2\n                        \n                    .","journal-title":"Lancet"},{"issue":"3","key":"551_CR66","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1191\/1352458504ms1044oa","volume":"10","author":"BW Oosten van","year":"2004","unstructured":"van Oosten BW, Killestein J, Mathus-Vliegen EMH, Polman CH. Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist. Mult Scler. 2004;10(3):330\u20131. doi:\n                        10.1191\/1352458504ms1044oa\n                        \n                    .","journal-title":"Mult Scler"},{"issue":"1","key":"551_CR67","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1159\/000110294","volume":"12","author":"L Brosseau","year":"1993","unstructured":"Brosseau L, Philippe P, Methot G, Duquette P, Haraoui B. Drug-abuse as a risk factor of multiple-sclerosis\u2014case-control analysis and a study of heterogeneity. Neuroepidemiology. 1993;12(1):6\u201314. doi:\n                        10.1159\/000110294\n                        \n                    .","journal-title":"Neuroepidemiology."},{"issue":"8","key":"551_CR68","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/pds.3269","volume":"21","author":"B Pasternak","year":"2012","unstructured":"Pasternak B, Svanstrom H, Nielsen NM, Melbye M, Hviid A. Use of amiloride and multiple sclerosis: registry-based cohort studies. Pharmacoepidemiol Drug Saf. 2012;21(8):890\u20135. doi:\n                        10.1002\/pds.3269\n                        \n                    .","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"551_CR69","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1212\/01.wnl.0000198507.13597.45","volume":"66","author":"A Alonso","year":"2006","unstructured":"Alonso A, Jick SS, Hernan MA. Allergy, histamine 1 receptor blockers, and the risk of multiple sclerosis. Neurology. 2006;66(4):572\u20135. doi:\n                        10.1212\/01.wnl.0000198507.13597.45\n                        \n                    .","journal-title":"Neurology."},{"issue":"4","key":"551_CR70","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S1474-4422(14)70028-6","volume":"13","author":"L Kappos","year":"2014","unstructured":"Kappos L, Hartung HP, Freedman MS, Boyko A, Radu EW, Mikol DD, et al. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol. 2014;13(4):353\u201363. doi:\n                        10.1016\/S1474-4422(14)70028-6\n                        \n                    .","journal-title":"Lancet Neurol."},{"issue":"Suppl 1","key":"551_CR71","doi-asserted-by":"crossref","first-page":"I121","DOI":"10.1136\/ard.58.2008.i121","volume":"58","author":"C Lock","year":"1999","unstructured":"Lock C, Oksenberg J, Steinman L. The role of TNFalpha and lymphotoxin in demyelinating disease. Ann Rheum Dis. 1999;58(Suppl 1):I121\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"2\u20133","key":"551_CR72","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0165-5728(91)90125-Q","volume":"34","author":"Y Kuroda","year":"1991","unstructured":"Kuroda Y, Shimamoto Y. Human tumor necrosis factor-alpha augments experimental allergic encephalomyelitis in rats. J Neuroimmunol. 1991;34(2\u20133):159\u201364.","journal-title":"J Neuroimmunol"},{"issue":"1","key":"551_CR73","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.autrev.2013.09.002","volume":"13","author":"E Kaltsonoudis","year":"2014","unstructured":"Kaltsonoudis E, Voulgari PV, Konitsiotis S, Drosos AA. Demyelination and other neurological adverse events after anti-TNF therapy. Autoimmun Rev. 2014;13(1):54\u20138. doi:\n                        10.1016\/j.autrev.2013.09.002\n                        \n                    .","journal-title":"Autoimmun Rev"},{"issue":"9","key":"551_CR74","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1002\/1529-0131(200109)44:9<1977::Aid-Art345>3.0.Co;2-6","volume":"44","author":"WH Robinson","year":"2001","unstructured":"Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism\u2014by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum. 2001;44(9):1977\u201383. doi:\n                        10.1002\/1529-0131(200109)44:9<1977:Aid-Art345>3.0.Co;2-6\n                        \n                    .","journal-title":"Arthritis Rheum"},{"issue":"6","key":"551_CR75","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00281-016-0584-y","volume":"38","author":"SM Gold","year":"2016","unstructured":"Gold SM, Voskuhl RR. Pregnancy and multiple sclerosis: from molecular mechanisms to clinical application. Semin Immunopathol. 2016;38(6):709\u201318. doi:\n                        10.1007\/s00281-016-0584-y\n                        \n                    .","journal-title":"Semin Immunopathol."},{"issue":"1\u20132","key":"551_CR76","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jns.2009.04.038","volume":"286","author":"A Alonso","year":"2009","unstructured":"Alonso A, Clark CJ. Oral contraceptives and the risk of multiple sclerosis: a review of the epidemiologic evidence. J Neurol Sci. 2009;286(1\u20132):73\u20135. doi:\n                        10.1016\/j.jns.2009.04.038\n                        \n                    .","journal-title":"J Neurol Sci"},{"issue":"12","key":"551_CR77","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/qjmed\/hci135","volume":"98","author":"CH Hawkes","year":"2005","unstructured":"Hawkes CH. Are multiple sclerosis patients risk-takers? Qjm. 2005;98(12):895\u2013911. doi:\n                        10.1093\/qjmed\/hci135\n                        \n                    .","journal-title":"Qjm"},{"key":"551_CR78","doi-asserted-by":"publisher","first-page":"635","DOI":"10.3389\/fimmu.2015.00635","volume":"6","author":"D Khan","year":"2015","unstructured":"Khan D, Ansar Ahmed S. The immune system is a natural target for estrogen action: opposing effects of estrogen in two prototypical autoimmune diseases. Front Immunol. 2015;6:635. doi:\n                        10.3389\/fimmu.2015.00635\n                        \n                    .","journal-title":"Front Immunol."},{"key":"551_CR79","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jneuroim.2016.02.009","volume":"293","author":"G Benedek","year":"2016","unstructured":"Benedek G, Zhang J, Bodhankar S, Nguyen H, Kent G, Jordan K, et al. Estrogen induces multiple regulatory B cell subtypes and promotes M2 microglia and neuroprotection during experimental autoimmune encephalomyelitis. J Neuroimmunol. 2016;293:45\u201353. doi:\n                        10.1016\/j.jneuroim.2016.02.009\n                        \n                    .","journal-title":"J Neuroimmunol"},{"issue":"25","key":"551_CR80","doi-asserted-by":"publisher","first-page":"6823","DOI":"10.1523\/JNEUROSCI.0453-06.2006","volume":"26","author":"LB Morales","year":"2006","unstructured":"Morales LB, Loo KK, Liu HB, Peterson C, Tiwari-Woodruff S, Voskuhl RR. Treatment with an estrogen receptor alpha ligand is neuroprotective in experimental autoimmune encephalomyelitis. J Neurosci. 2006;26(25):6823\u201333. doi:\n                        10.1523\/JNEUROSCI.0453-06.2006\n                        \n                    .","journal-title":"J Neurosci"},{"issue":"12","key":"551_CR81","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1212\/WNL.0b013e31824c4648","volume":"78","author":"AL Ponsonby","year":"2012","unstructured":"Ponsonby AL, Lucas RM, van der Mei IA, Dear K, Valery PC, Pender MP, et al. Offspring number, pregnancy, and risk of a first clinical demyelinating event: the AusImmune Study. Neurology. 2012;78(12):867\u201374. doi:\n                        10.1212\/WNL.0b013e31824c4648\n                        \n                    .","journal-title":"Neurology."},{"issue":"8","key":"551_CR82","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/ene.13026","volume":"23","author":"H Tremlett","year":"2016","unstructured":"Tremlett H, Fadrosh DW, Faruqi AA, Zhu F, Hart J, Roalstad S, et al. Gut microbiota in early pediatric multiple sclerosis: a case-control study. Eur J Neurol. 2016;23(8):1308\u201321. doi:\n                        10.1111\/ene.13026\n                        \n                    .","journal-title":"Eur J Neurol"},{"issue":"5","key":"551_CR83","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1097\/ACO.0000000000000107","volume":"27","author":"JR McSwain","year":"2014","unstructured":"McSwain JR, Doty JW, Wilson SH. Regional anesthesia in patients with pre-existing neurologic disease. Curr Opin Anaesthesiol. 2014;27(5):538\u201343. doi:\n                        10.1097\/ACO.0000000000000107\n                        \n                    .","journal-title":"Curr Opin Anaesthesiol."},{"issue":"9","key":"551_CR84","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1136\/jnnp-2015-312591","volume":"87","author":"F Patti","year":"2016","unstructured":"Patti F, Messina S, Solaro C, Amato MP, Bergamaschi R, Bonavita S, et al. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. J Neurol Neurosurg Psychiatry. 2016;87(9):944\u201351. doi:\n                        10.1136\/jnnp-2015-312591\n                        \n                    .","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"551_CR85","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1111\/nmo.12931","volume":"28","author":"C Hasenoehrl","year":"2016","unstructured":"Hasenoehrl C, Taschler U, Storr M, Schicho R. The gastrointestinal tract\u2014a central organ of cannabinoid signaling in health and disease. Neurogastroenterol Motil. 2016;28(12):1765\u201380. doi:\n                        10.1111\/nmo.12931\n                        \n                    .","journal-title":"Neurogastroenterol Motil"},{"key":"551_CR86","doi-asserted-by":"publisher","unstructured":"Fitzpatrick JK, Downer EJ. Toll-like receptor signalling as a cannabinoid target in multiple sclerosis. Neuropharmacology. 2017;113(Pt B):618\u201326. doi:\n                        10.1016\/j.neuropharm.2016.04.009\n                        \n                    .","DOI":"10.1016\/j.neuropharm.2016.04.009"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-017-0551-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0551-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0551-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T05:21:39Z","timestamp":1503465699000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-017-0551-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,9]]},"references-count":86,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["551"],"URL":"https:\/\/doi.org\/10.1007\/s40264-017-0551-0","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"type":"print","value":"0114-5916"},{"type":"electronic","value":"1179-1942"}],"subject":[],"published":{"date-parts":[[2017,6,9]]}}}